{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:22:09Z","timestamp":1793496129381,"version":"4.5.0"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007525","name":"University of Rennes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.parkreldis.2025.107872","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:13:45Z","timestamp":1747163625000},"page":"107872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Apomorphine: past, present and future in Parkinson's disease and beyond"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4084","authenticated-orcid":false,"given":"Manon","family":"Auffret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107872_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2190\/1C99-R30J-LGM6-K5HX","article-title":"Serendipity and drugs: an historical perspective","volume":"2","author":"Swanson","year":"1972","journal-title":"J. Drug Educ."},{"key":"10.1016\/j.parkreldis.2025.107872_bib2","first-page":"342","article-title":"The structure of serendipity, Cult","volume":"20","author":"de Rond","year":"2014","journal-title":"Organ"},{"key":"10.1016\/j.parkreldis.2025.107872_bib3","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2017.17914","article-title":"From sgt. Pepper to dreamachines: my scientific odyssey with william S. Burroughs","volume":"318","author":"Lees","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2025.107872_bib4","first-page":"335","article-title":"The role of serendipity in drug discovery, Dialogues Clin","volume":"8","author":"Ban","year":"2006","journal-title":"Neurosci"},{"key":"10.1016\/j.parkreldis.2025.107872_bib5","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.1957.72980340011013","article-title":"Serendipity; big word in medical progress","volume":"165","author":"Golin","year":"1957","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","article-title":"Amantadine in the treatment of Parkinson's disease","volume":"208","author":"Schwab","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2025.107872_bib7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jama.1972.03210070026008","article-title":"Amantadine in Parkinson's disease. Review of more than two years' experience","volume":"222","author":"Schwab","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2025.107872_bib8","first-page":"85","article-title":"Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease","volume":"94","author":"Schwab","year":"1969","journal-title":"Trans. Am. Neurol. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib9","first-page":"251","article-title":"Apomorphine in Parkinson's disease","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans. Am. Neurol. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40268-018-0230-3","article-title":"The many faces of apomorphine: lessons from the past and challenges for the future","volume":"18","author":"Auffret","year":"2018","journal-title":"Drugs R&D"},{"key":"10.1016\/j.parkreldis.2025.107872_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF00403900","article-title":"Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats","volume":"10","author":"Ernst","year":"1967","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.parkreldis.2025.107872_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"1996","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.parkreldis.2025.107872_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/mdc3.13810","article-title":"Continuous subcutaneous infusion delivery of apomorphine in Parkinson's disease: a systematic review","volume":"10","author":"Kukkle","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mdc3.13593","article-title":"Intermittent apomorphine use for off period rescue in Parkinson's disease: a pragmatic review of over three decades of clinical experience","volume":"10","author":"Castillo-Torres","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","article-title":"How should systematic reviewers handle conference abstracts? A view from the trenches","volume":"8","author":"Scherer","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.parkreldis.2025.107872_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjd.19504","article-title":"The value of case reports in pharmacovigilance","volume":"183","author":"Garcia\u2010Doval","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.parkreldis.2025.107872_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-5-3","article-title":"Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)","volume":"5","author":"Mencher","year":"2005","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib19","doi-asserted-by":"crossref","unstructured":"A. Matthiessen, C.R.A. Wright, Researches into the Chemical Constitution of the Opium Bases. Part I.--On the Action of Hydrochloric Acid on Morphia, Proc. Roy. Soc. Lond. 17 (1869) 455\u2013460. https:\/\/www.jstor.org\/stable\/112441 (accessed January 30, 2025).","DOI":"10.1098\/rspl.1868.0094"},{"key":"10.1016\/j.parkreldis.2025.107872_bib20","doi-asserted-by":"crossref","unstructured":"A.E. Arppe, Ueber eine merkw\u00fcrdige Ver\u00e4nderung des Morphins durch Schwefels\u00e4ure, Justus Liebigs Ann. Chem. 55 (1845) 96\u2013101. https:\/\/doi.org\/10.1002\/jlac.18450550107.","DOI":"10.1002\/jlac.18450550107"},{"key":"10.1016\/j.parkreldis.2025.107872_bib21","first-page":"396","volume":"33","author":"Edinb","year":"1848","journal-title":"Dublin Philos. Mag. J. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib22","first-page":"726","article-title":"Sulfomorphid; and the purple fluorescence test, A new derivative test for morphine","volume":"26","author":"Fulton","year":"1912","journal-title":"J. Am. Pharmaceut. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib23","doi-asserted-by":"crossref","unstructured":"T. Anderson, III.\u2014On the Constitution of Codeine and its Products of Decomposition, Earth Environ. Sci. Trans. R. Soc. Edinb. 20 (1853) 57\u201385. https:\/\/doi.org\/10.1017\/S0080456800033032.","DOI":"10.1017\/S0080456800033032"},{"key":"10.1016\/j.parkreldis.2025.107872_bib24","doi-asserted-by":"crossref","unstructured":"Notes, Nature 3 (1870) 132\u2013134. https:\/\/doi.org\/10.1038\/003132a0.","DOI":"10.1038\/003132a0"},{"key":"10.1016\/j.parkreldis.2025.107872_bib25","doi-asserted-by":"crossref","unstructured":"Notes, Nature 2 (1870) 12\u201315. https:\/\/doi.org\/10.1038\/002012b0.","DOI":"10.1038\/002012b0"},{"key":"10.1016\/j.parkreldis.2025.107872_bib26","doi-asserted-by":"crossref","unstructured":"Notes, Nature 1 (1869) 113\u2013114. https:\/\/doi.org\/10.1038\/001113a0.","DOI":"10.1038\/001113a0"},{"key":"10.1016\/j.parkreldis.2025.107872_bib27","doi-asserted-by":"crossref","unstructured":"Augustus Matthiessen, Nature 2 (1870) 517\u2013518. https:\/\/doi.org\/10.1038\/002517c0.","DOI":"10.1038\/002517c0"},{"key":"10.1016\/j.parkreldis.2025.107872_bib28","doi-asserted-by":"crossref","unstructured":"Medical Diary of the Week., Lancet 93 (1869) 661. https:\/\/doi.org\/10.1016\/S0140-6736(02)35344-3.","DOI":"10.1016\/S0140-6736(02)35344-3"},{"key":"10.1016\/j.parkreldis.2025.107872_bib29","unstructured":"S.J. Gee, On the action of a new organic base, apomorphia, Trans. Clin. Soc. Lond. 2 (1869) 166\u2013169."},{"key":"10.1016\/j.parkreldis.2025.107872_bib30","series-title":"(London), Saint Bartholomew's Hospital Reports","author":"of","year":"1869"},{"key":"10.1016\/j.parkreldis.2025.107872_bib31","series-title":"The Cincinnati Lancet and Observer, E.B. Stevens","year":"1869"},{"key":"10.1016\/j.parkreldis.2025.107872_bib32","first-page":"7","article-title":"Article clipped from the guardian","year":"1869","journal-title":"Guardian"},{"key":"10.1016\/j.parkreldis.2025.107872_bib33","first-page":"75","article-title":"Neuralgia-introduction of medicated fluid to the nerve, ill","volume":"2","author":"Rynd","year":"1845","journal-title":"Med. Surg. J."},{"key":"10.1016\/j.parkreldis.2025.107872_bib34","unstructured":"Comptes Rendus Hebdomadaires des S\u00e9ances de l\u2019Acad\u00e9mie des Sciences 1853-01-10: Vol 36 Iss 2, 1853. http:\/\/archive.org\/details\/comptes-rendus-hebdomadaires-academie-des-sciences_1853-01-10_36_2 (accessed January 31, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib35","unstructured":"A. Wood, New Method of Treating Neuralgia by the Direct Application of Opiates to the Painful Points, Edinb. Med. Surg. J. 82 (1855) 265\u2013281. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5846403\/(accessed January 31, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.1916.02580380006003","article-title":"The history of intravenous and subcutaneous administration of drugs","volume":"LXVI","author":"Macht","year":"1916","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib37","author":"Routy"},{"key":"10.1016\/j.parkreldis.2025.107872_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmj.1.478.204","article-title":"Notes on apomorphia","volume":"1","author":"Pierce","year":"1870","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2025.107872_bib39","unstructured":"A.P.A.A. Meeting, A.P. Association, Proceedings of the American Pharmaceutical Association at the Annual Meeting, the Association, 1875."},{"key":"10.1016\/j.parkreldis.2025.107872_bib40","first-page":"75","article-title":"Notes of a case of dhatura poisoning","volume":"18","author":"Campbell","year":"1883","journal-title":"Indian Med. Gaz."},{"key":"10.1016\/j.parkreldis.2025.107872_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/15563657508990076","article-title":"Drugs of abuse in the future","volume":"8","author":"Shulgin","year":"1975","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib42","first-page":"911","volume":"LXIV","year":"1915","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib43","first-page":"161","article-title":"Concerning new provisions and instructions regarding California narcotic laws","volume":"55","author":"Madden","year":"1941","journal-title":"Calif. West. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00480169.1961.33442","article-title":"Some effects of drugs in the \u201cdoping\u201d of racehorses","volume":"9","author":"Mackay","year":"1961","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.parkreldis.2025.107872_bib45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1192\/bjp.115.523.723","article-title":"Subjective and penile plethysmograph responses following aversion-relief and apomorphine aversion therapy for homosexual impulses","volume":"115","author":"McConaghy","year":"1969","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib46","first-page":"180","article-title":"Some observations on the use of apomorphine, Atlanta J.-Rec","volume":"59","author":"Horsley","year":"1912","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.parkreldis.2025.107872_bib47","first-page":"411","article-title":"De l\u2019apomorphine dans certains troubles nerveux, Lyon M\u00e9d. Gaz","author":"Weill","year":"1884","journal-title":"M\u00e9dicale J. M\u00e9decine R\u00e9un"},{"key":"10.1016\/j.parkreldis.2025.107872_bib48","series-title":"Note sur l\u2019action th\u00e9rapeutique de l\u2019apomorphine","author":"Georges","year":"1874"},{"key":"10.1016\/j.parkreldis.2025.107872_bib49","series-title":"De l'Apomorphine, recherches cliniques sur un nouvel \u00e9m\u00e9tique","author":"J-B-Victor","year":"1874"},{"key":"10.1016\/j.parkreldis.2025.107872_bib51","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson's disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib52","first-page":"74","article-title":"Apomorphia hydrochloride","volume":"33","author":"Anderson","year":"1935","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.parkreldis.2025.107872_bib53","first-page":"541","article-title":"The effect of apomorphine and that of adrenalin, on the tremor of Parkinson's disease, J. Nerv. Ment","volume":"114","author":"Barcroft","year":"1951","journal-title":"Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib54","first-page":"295","article-title":"Unexpected findings with apomorphine and their possible consequences","volume":"5","author":"Cotzias","year":"1974","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib55","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM197012032832314","article-title":"Dopamine analogues for studies of parkinsonism","volume":"283","author":"Cotzias","year":"1970","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0028-1094348","article-title":"Tremor inhibition in Parkinson syndrome after apomorphine administration under L-dopa and decarboxylase-inhibitor basic therapy","volume":"5","author":"Strian","year":"1972","journal-title":"Pharmacopsychiatry"},{"issue":"Pt 2","key":"10.1016\/j.parkreldis.2025.107872_bib57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/107.2.487","article-title":"On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study","volume":"107","author":"Hardie","year":"1984","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","article-title":"Role of subcutaneous apomorphine in parkinsonian voiding dysfunction","volume":"2","author":"Christmas","year":"1988","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.parkreldis.2025.107872_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)91193-2","article-title":"Subcutaneous apomorphine in parkinsonian on-off oscillations","volume":"1","author":"Stibe","year":"1988","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.parkreldis.2025.107872_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mds.870040108","article-title":"Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine","volume":"4","author":"Kempster","year":"1989","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib61","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/jnnp.53.11.1004","article-title":"Comparison of motor response to apomorphine and levodopa in Parkinson's disease","volume":"53","author":"Kempster","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107872_bib62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jnnp.53.2.96","article-title":"Subcutaneous apomorphine in the treatment of Parkinson's disease","volume":"53","author":"Frankel","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107872_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0140-6736(90)91531-E","article-title":"Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes","volume":"336","author":"Hughes","year":"1990","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.parkreldis.2025.107872_bib64","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00002826-199008000-00005","article-title":"Apomorphine in the diagnosis and treatment of parkinsonian tremor","volume":"13","author":"Hughes","year":"1990","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp.54.4.358","article-title":"The motor response to sequential apomorphine in parkinsonian fluctuations","volume":"54","author":"Hughes","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107872_bib66","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1212\/WNL.41.11.1723","article-title":"Challenge tests to predict the dopaminergic response in untreated Parkinson's disease","volume":"41","author":"Hughes","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00002826-198902000-00002","article-title":"Motor response following repeated apomorphine administration is reduced in Parkinson's disease","volume":"12","author":"Grandas","year":"1989","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib68","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.42.7.1287","article-title":"Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease","volume":"42","author":"Grandas","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib69","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1017\/S0317167100037963","article-title":"Continuous dopaminergic stimulation in Parkinson's disease","volume":"14","author":"Obeso","year":"1987","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib70","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(87)90679-9","article-title":"Apomorphine infusion for motor fluctuations in Parkinson's disease","volume":"1","author":"Obeso","year":"1987","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.parkreldis.2025.107872_bib71","doi-asserted-by":"crossref","unstructured":"A.E. Martinez-Nunez, P.A. LeWitt, Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease, J. Park. Dis. 13 (n.d.) 441\u2013451. https:\/\/doi.org\/10.3233\/JPD-230055.","DOI":"10.3233\/JPD-230055"},{"key":"10.1016\/j.parkreldis.2025.107872_bib72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00702-024-02777-z","article-title":"Sublingual apomorphine in the treatment of Parkinson's disease","volume":"131","author":"Kassubek","year":"1996","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.parkreldis.2025.107872_bib73","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2147\/PPA.S301644","article-title":"Patient preferences for treating \u201coff\u201d episodes in Parkinson's disease: a discrete choice experiment","volume":"15","author":"Thach","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.parkreldis.2025.107872_bib74","first-page":"1329","article-title":"CTH-302 study investigators, apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson's disease: an open-label, randomized, crossover study","volume":"13","author":"Stocchi","year":"2023","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36469\/jheor.2021.29488","article-title":"Cost-effectiveness of apomorphine sublingual film as an \u201con-demand\u201d treatment for \u201cOFF\u201d episodes in patients with Parkinson's disease","volume":"8","author":"Thach","year":"2021","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.parkreldis.2025.107872_bib76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10928-024-09914-x","article-title":"Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease","volume":"51","author":"Nasser","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.parkreldis.2025.107872_bib77","first-page":"1507","article-title":"Oral health disorders in Parkinson's disease: more than meets the eye","volume":"11","author":"Auffret","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib78","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/cts.13008","article-title":"Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease","volume":"14","author":"Agbo","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/mds.30162","article-title":"Update on treatments for Parkinson's disease motor fluctuations - an international Parkinson and movement disorder society evidence-based medicine review","author":"de Bie","year":"2025","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib81","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00702-023-02686-7","article-title":"Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience","volume":"130","author":"Henriksen","year":"1996","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.parkreldis.2025.107872_bib82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mdc3.12717","article-title":"Apomorphine, more evidence for an old drug: a key for therapy generalization?","volume":"6","author":"Ameghino","year":"2019","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib83","article-title":"Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long-term, open-label United States InfusON study","author":"Isaacson","year":"2025","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib84","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mdc3.13799","article-title":"Post\u2010hoc analysis of the APOMORPHEE study, night-time apomorphine infusion: who are the best candidates?","volume":"10","author":"Cochen De Cock","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib85","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","article-title":"Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study","volume":"21","author":"De","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib86","doi-asserted-by":"crossref","DOI":"10.4081\/ni.2019.8207","article-title":"Investigation of apomorphine during sleep in Parkinson's: improvement in UPDRS scores","volume":"11","author":"Pieroni","year":"2019","journal-title":"Neurol. Int."},{"key":"10.1016\/j.parkreldis.2025.107872_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","article-title":"Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome","volume":"100","author":"Reuter","year":"1999","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2025.107872_bib88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10072-003-0133-z","article-title":"Nocturnal anomalous movementreduction and sleep microstructure analysis in parkinsonianpatients during 1-night transdermal apomorphinetreatment","volume":"24","author":"Priano","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib89","article-title":"Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: a prospective study of 22 patients","volume":"6","author":"Fern\u00e1ndez-Pajar\u00edn","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.107872_bib90","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.parkreldis.2016.11.016","article-title":"Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors","volume":"33","author":"Bhidayasiri","year":"2016","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib91","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.parkreldis.2025.107872_bib92","first-page":"209","article-title":"Terminal care in Parkinson's disease: real-life use of continuous subcutaneous apomorphine infusion to improve patient comfort","volume":"14","author":"B\u00e9reau","year":"2024","journal-title":"J. Park. Dis"},{"key":"10.1016\/j.parkreldis.2025.107872_bib93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02226968","article-title":"Apomorphine in malignant syndrome due to levodopa withdrawal","volume":"13","author":"Bonuccelli","year":"1992","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib94","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.41.6.942","article-title":"Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction","volume":"41","author":"Cunningham","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib95","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1212\/01.WNL.0000157058.17871.7B","article-title":"Acute akinesia in Parkinson disease","volume":"64","author":"Onofrj","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib96","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10072-003-0139-6","article-title":"Acute akinesia or akinetic crisis inParkinson's disease","volume":"24","author":"Thomas","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib97","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/cjn.2020.211","article-title":"A pragmatic approach to the perioperative management of Parkinson's disease","volume":"48","author":"Lenka","year":"2021","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib98","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/anae.15617","article-title":"Peri-operative management of patients with Parkinson's disease","volume":"77","author":"Yim","year":"2022","journal-title":"Anaesthesia"},{"key":"10.1016\/j.parkreldis.2025.107872_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40734-021-00091-4","article-title":"Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson's disease patient","volume":"7","author":"Spagnolo","year":"2021","journal-title":"J. Clin. Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib100","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archneurol.2010.220","article-title":"Dopamine agonist withdrawal syndrome: the apomorphine solution","volume":"67","author":"Schlesinger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib101","unstructured":"Apomorphine improves pulmonary function in parkinsonian patients [abstract]. Mov Disord. 2020; 35 (suppl 1). https:\/\/www.mdsabstracts.org\/abstract\/apomorphine-improves-pulmonary-function-in-parkinsonian-patients\/. Accessed May 14, 2025."},{"key":"10.1016\/j.parkreldis.2025.107872_bib102","unstructured":"May apomorphine be helpful for the axial symptoms of Parkinson's Disease?, MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/may-apomorphine-be-helpful-for-the-axial-symptoms-of-parkinsons-disease\/(accessed January 22, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.parkreldis.2020.05.015","article-title":"The long-term effect of continuous subcutaneous apomorphine infusions on camptocormia in Parkinson's disease","volume":"75","author":"Men\u0161\u00edkov\u00e1","year":"2020","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib104","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00702-014-1297-9","article-title":"Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study","volume":"122","author":"Mensikova","year":"1996","journal-title":"J. Neural Transm. Vienna Austria"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.107872_bib105","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2016.11.020","article-title":"The efficacy of apomorphine - a non-motor perspective","volume":"33","author":"Rosa-Grilo","year":"2016","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70077","article-title":"Cognitive outcomes of advanced therapies in Parkinson's disease: a systematic review of apomorphine and levodopa\u2013carbidopa intestinal gel therapies","volume":"32","author":"Longo","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib107","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","article-title":"Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase","volume":"58","author":"De Wit","year":"2022","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/0004-282x-anp-2020-0522","article-title":"The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis","volume":"80","author":"Barbosa","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.parkreldis.2025.107872_bib109","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40360-025-00886-3","article-title":"Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data","volume":"26","author":"Mu","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib111","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2020.1806059","article-title":"\u201cDopamine agonist Phobia\u201d in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine","volume":"20","author":"Rota","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2025.107872_bib112","article-title":"Parkinson's disease subtypes: approaches and clinical implications","volume":"130","author":"Deng","year":"2025","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib113","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/jpm11080773","article-title":"Personalised advanced therapies in Parkinson's disease: the role of non-motor symptoms profile","volume":"11","author":"Leta","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib114","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.clinph.2015.11.022","article-title":"2. Antecollis associated with Parkinson's disease improved following apomorphine therapy","volume":"127","author":"Yin","year":"2016","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib115","unstructured":"The Effects of Apomorphine infusion on Head ptosis, a case report, MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/the-effects-of-apomorphine-infusion-on-head-ptosis-a-case-report\/(accessed February 19, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib116","unstructured":"Apomorphine effects on Parkinson's disease fluctuation related pain: a pilot study, MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/apomorphine-effects-on-parkinsons-disease-fluctuation-related-pain-a-pilot-study\/(accessed November 1, 2023)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib117","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1468-1331.2004.00942.x","article-title":"Postural stability of Parkinson's disease patients is improved by decreasing rigidity","volume":"12","author":"Bartoli\u0107","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib118","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1368-5031.2004.00357.x","article-title":"Diagnostic and therapeutic value of apomorphine in Parkinsonian patients","volume":"58","author":"Sharma","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib119","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/mdc3.13907","article-title":"Apomorphine at the end-of-life-A role to play","volume":"10","author":"Azoia","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0269216309106979","article-title":"The pragmatic use of apomorphine at the end of life","volume":"23","author":"Dewhurst","year":"2009","journal-title":"Palliat. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib121","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4081\/aiua.2022.1.107","article-title":"Perspectives on the urological care in Parkinson's disease patients","volume":"94","author":"Moussa","year":"2022","journal-title":"Arch. Ital. Urol. Androl. Organo Uff. Soc. Ital. Ecogr. Urol. E Nefrol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib122","unstructured":"Perioperative sublingual levodopa in Parkisnon's Disease: A useful alternative! - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/28584355\/(accessed February 21, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib123","series-title":"Day Case Initiation of Subcutaneous Apomorphine in People with Parkinson's Disease: A Retrospective Analysis from a UK Teaching Hospital","author":"Nalamada","year":"2016"},{"key":"10.1016\/j.parkreldis.2025.107872_bib124","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-023-02609-6","article-title":"APOKADO Group, Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study","volume":"130","author":"Zagnoli","year":"2023","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.parkreldis.2025.107872_bib125","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-023-02710-w","article-title":"Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice","volume":"130","author":"Kobylecki","year":"2023","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.parkreldis.2025.107872_bib126","first-page":"133","article-title":"[Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations]","volume":"22","author":"Casta\u00f1o","year":"2007","journal-title":"Neurol. Barc. Spain"},{"key":"10.1016\/j.parkreldis.2025.107872_bib127","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12968\/bjnn.2016.12.2.70","article-title":"A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease","volume":"12","author":"Price","year":"2016","journal-title":"Br. J. Neurosci. Nurs."},{"key":"10.1016\/j.parkreldis.2025.107872_bib128","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.14345","article-title":"Assessing eligibility for apomorphine therapy in Parkinson's disease: the telemonitoring potential","author":"Niruban","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.107872_bib129","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.parkreldis.2016.11.014","article-title":"Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy","volume":"33","author":"Bhidayasiri","year":"2016","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib130","article-title":"The Parkinson's disease nurse specialist and subcutaneous apomorphine infusion. A Scoping Review of the literature","volume":"95","author":"Conte","year":"2024","journal-title":"Acta Biomed. Atenei Parm"},{"key":"10.1016\/j.parkreldis.2025.107872_bib131","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12968\/bjcn.2022.27.7.328","article-title":"Sublingual apomorphine therapy as an alternative to complex continuous infusion pumps in advanced Parkinson's disease treatment: a district nurse-led intervention","volume":"27","author":"Macaulay","year":"2022","journal-title":"Br. J. Community Nurs."},{"key":"10.1016\/j.parkreldis.2025.107872_bib132","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231209240","article-title":"CTH-302 Study Investigators\u2217, Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study","volume":"16","author":"Kassubek","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib133","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1080\/03007995.2021.1953971","article-title":"Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions","volume":"37","author":"Jick","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.parkreldis.2025.107872_bib134","article-title":"Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients","volume":"116","author":"Camgrand","year":"2023","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/WNF.0000000000000361","article-title":"Long-term apomorphine infusion users versus short-term users: an international dual-center analysis of the reasons for discontinuing therapy","volume":"42","author":"Bhidayasiri","year":"2019","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib136","article-title":"Loss of awareness after continuous apomorphine infusion withdrawal in Parkinson's disease","volume":"47","author":"Oliveira","year":"2020","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2019.07.011","article-title":"Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease","volume":"404","author":"Cavallieri","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib138","first-page":"1","article-title":"Accelerated symptom improvement in Parkinson's disease via remote internet-based optimization of deep brain stimulation therapy: a randomized controlled multicenter trial, Commun","volume":"5","author":"Gharabaghi","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.parkreldis.2025.107872_bib139","article-title":"A multidisciplinary telemedicine approach for managing frailty in Parkinson's disease. A longitudinal, case-control study","volume":"130","author":"Garc\u00eda-Bustillo","year":"2025","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib140","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.parkreldis.2015.04.030","article-title":"Remote control of apomorphine infusion rate in Parkinson's disease: real-time dose variations according to the patients' motor state. A proof of concept","volume":"21","author":"Rodr\u00edguez-Molinero","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib141","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mdc3.13593","article-title":"Intermittent apomorphine use for off period rescue in Parkinson's disease: a pragmatic review of over three decades of clinical experience","volume":"10","author":"Castillo\u2010Torres","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib142","article-title":"Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: a modified Delphi panel","volume":"11","author":"Isaacson","year":"2024","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib143","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.parkreldis.2014.08.010","article-title":"Tigan\/Apokyn Study Investigators, Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection","volume":"20","author":"Hauser","year":"2014","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib144","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mdc3.12350","article-title":"Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease","volume":"4","author":"Isaacson","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","article-title":"Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach","volume":"23","author":"Lees","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2025.107872_bib146","article-title":"Should \u201con-demand\u201d treatments for Parkinson's disease OFF episodes be used earlier?","volume":"7","author":"Isaacson","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib147","first-page":"407","article-title":"Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability","volume":"32","author":"Salazar","year":"2017","journal-title":"Neurol. Engl. Ed."},{"key":"10.1016\/j.parkreldis.2025.107872_bib148","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/mdc3.13338","article-title":"Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients","volume":"8","author":"Fern\u00e1ndez-Pajar\u00edn","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib149","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.14802\/jmd.23057","article-title":"Apomorphine monotherapy for Parkinson's disease: a neglected option?","volume":"16","author":"Desjardins","year":"2023","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.26444\/aaem\/99699","article-title":"Continuous subcutaneous apomorphine monotherapy in Parkinson's disease","volume":"26","author":"Papu\u0107","year":"2019","journal-title":"Ann. Agric. Environ. Med. AAEM"},{"key":"10.1016\/j.parkreldis.2025.107872_bib152","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/0006-2952(73)90014-2","article-title":"Evidence for the methylation of apomorphine by catechol-O-methyl-transferase in vivo and in vitro","volume":"22","author":"McKenzie","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib153","doi-asserted-by":"crossref","DOI":"10.1080\/14737175.2021.1968298","article-title":"Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone","author":"Jenner","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2025.107872_bib154","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mds.20188","article-title":"Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study","volume":"19","author":"Zijlmans","year":"2004","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1353-8020(00)00019-5","article-title":"The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease","volume":"6","author":"Ondo","year":"2000","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib156","author":"Patel"},{"key":"10.1016\/j.parkreldis.2025.107872_bib157","first-page":"1527","article-title":"Winding back the clock on advanced therapies: it's time to get smart","volume":"14","author":"Georgiades","year":"2024","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib158","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","article-title":"Device-aided treatment strategies in advanced Parkinson's disease","volume":"132","author":"Timpka","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib159","doi-asserted-by":"crossref","first-page":"10","DOI":"10.18773\/austprescr.2025.003","article-title":"Device-assisted therapies for Parkinson disease","volume":"48","author":"Mouchaileh","year":"2025","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.parkreldis.2025.107872_bib160","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.mehy.2008.11.031","article-title":"Treatment of Parkinson's disease could be regulated by movement sensors: subcutaneous infusion of varying apomorphine doses according to the intensity of motor activity","volume":"72","author":"Rodr\u00edguez-Molinero","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.parkreldis.2025.107872_bib161","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41582-022-00674-1","article-title":"Closing the loop for patients with Parkinson disease: where are we?","volume":"18","author":"Teymourian","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib162","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/bmj.316.7132.641","article-title":"Subcutaneous apomorphine in Parkinson's disease","volume":"316","author":"Chaudhuri","year":"1998","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2025.107872_bib163","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/mds.27906","article-title":"Bridging the gaps: more inclusive research needed to fully understand Parkinson's disease","volume":"35","author":"Gilbert","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib165","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70024","article-title":"How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis","volume":"32","author":"Smilowska","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib166","first-page":"1","article-title":"Using a sex- and gender-informed lens to enhance care in Parkinson's disease","author":"Castro-Aldrete","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.14337","article-title":"Unraveling hormonal influence of menstrual cycle in a young patient with LRRK2-Parkinson\u2019s disease","author":"Ferreira","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib168","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ane.12929","article-title":"Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy","volume":"138","author":"Sahlstr\u00f6m","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2025.107872_bib169","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41531-023-00513-0","article-title":"Time to workforce exit after a Parkinson's disease diagnosis","volume":"9","author":"Timpka","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib170","first-page":"1023","article-title":"Movement disorders society epidemiology study group, surveying global availability of Parkinson's disease treatment","volume":"12","author":"Goh","year":"2022","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib171","doi-asserted-by":"crossref","first-page":"53","DOI":"10.14802\/jmd.17028","article-title":"Parkinson's disease in sub-saharan Africa: a review of epidemiology, genetics and access to care","volume":"11","author":"Williams","year":"2018","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib172","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1136\/ejhpharm-2020-002461","article-title":"Pharmacotherapeutic management of Parkinson's disease inpatients: how about asking hospital pharmacists?","volume":"28","author":"Lertxundi Etxebarria","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.parkreldis.2025.107872_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46003-4","article-title":"Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience","volume":"13","author":"Metta","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107872_bib174","first-page":"1","article-title":"Care access and utilization among medicare beneficiaries living with Parkinson's disease","volume":"9","author":"Pearson","year":"2023","journal-title":"Npj Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib175","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14737175.2020.1770598","article-title":"Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries","volume":"20","author":"Bhidayasiri","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2025.107872_bib176","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/tmj.2018.0101","article-title":"Telemedicine in neurological disorders: opportunities and challenges","volume":"25","author":"Chirra","year":"2019","journal-title":"Telemed. J. e Health"},{"key":"10.1016\/j.parkreldis.2025.107872_bib177","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00415-018-8816-9","article-title":"Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study","volume":"265","author":"Tessitore","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib178","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/NDT.S256217","article-title":"Impact of supporting people with advanced Parkinson's disease on carer's quality of life and burden","volume":"16","author":"Modugno","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.parkreldis.2025.107872_bib179","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2102","article-title":"Close relationships in Parkinson's disease patients with device-aided therapy","volume":"11","author":"Scharfenort","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2025.107872_bib180","first-page":"1","article-title":"Inclusion in neurological research: empowering people living with neurological diseases","author":"Ferretti","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib181","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2016.12.004","article-title":"Learning from patients: identifying design features of medicines that cause medication use problems","volume":"517","author":"Notenboom","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.parkreldis.2025.107872_bib182","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1212\/WNL.96.15_supplement.2356","article-title":"\u201cNeedle phobia\u201d in patients with Parkinson's disease (PD) experiencing OFF episodes is uncommon (2356)","volume":"96","author":"Imamovic","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib183","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/mdc3.14213","article-title":"Underutilization of injectable Parkinson's disease medication: an analysis of neurologist and patient perspectives","volume":"11","author":"Solis","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107872_bib184","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1212\/WNL.0000000000204229","article-title":"Neurologists' likelihood of prescribing injectable Parkinson's disease (PD) therapies increases with education on patient attitudes (P10-11.007)","volume":"100","author":"Kumar","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib185","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/00207454.2020.1853723","article-title":"Patient preference of device-based treatment of Parkinson's disease","volume":"132","author":"Aydemir","year":"2022","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib186","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.41.5.761-a","article-title":"Intranasal apomorphine in Parkinson's disease","volume":"41","author":"Kleedorfer","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107872_bib187","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/ane.12107","article-title":"Inhaled dry powder apomorphine (VR040) for \u2018off \u2019 periods in Parkinson's disease: an in-clinic double-blind dose ranging study","volume":"128","author":"Grosset","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2025.107872_bib188","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.parkreldis.2022.02.014","article-title":"Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients","volume":"97","author":"Thijssen","year":"2022","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib189","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/mds.28926","article-title":"A randomized trial assessing the safety, pharmacokinetics, and efficacy during morning off of AZ-009","volume":"37","author":"Thijssen","year":"2022","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107872_bib190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.nano.2019.01.014","article-title":"Effective encapsulation of apomorphine into biodegradable polymeric nanoparticles through a reversible chemical bond for delivery across the blood\u2013brain barrier","volume":"17","author":"Tan","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101965","article-title":"Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease","volume":"89","author":"Preetam","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.parkreldis.2025.107872_bib192","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13796","article-title":"Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients","volume":"17","author":"Thijssen","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib193","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1007\/s00415-020-10031-1","article-title":"Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease","volume":"267","author":"Hagell","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib194","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/biomedicines11051244","article-title":"A pig model to assess skin lesions after apomorphine application","volume":"11","author":"Martin","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.parkreldis.2025.107872_bib195","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40263-018-0512-x","volume":"32","author":"Ramot","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2025.107872_bib196","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/j.xphs.2020.05.017","article-title":"Controlled delivery of apomorphine through buccal mucosa, towards a noninvasive administration method in Parkinson's disease: a preclinical mechanistic study","volume":"109","author":"Itin","year":"2020","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib197","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.xphs.2020.12.010","article-title":"Prolonged delivery of apomorphine through the buccal mucosa, towards a noninvasive sustained administration method in Parkinson's disease: in vivo investigations in pigs","volume":"110","author":"Itin","year":"2021","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib198","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20054","article-title":"Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease","volume":"19","author":"Priano","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib199","doi-asserted-by":"crossref","first-page":"s99","DOI":"10.1007\/s100720200088","article-title":"Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease","volume":"23","author":"Priano","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40486-024-00204-2","article-title":"Engineering microscopic delivery systems: a review of dissolving microneedle design, fabrication, and function","volume":"12","author":"Dave","year":"2024","journal-title":"Micro Nano Syst. Lett."},{"key":"10.1016\/j.parkreldis.2025.107872_bib201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11095-023-03621-x","article-title":"Fabrication and characterization of dissolving microneedles for transdermal drug delivery of apomorphine hydrochloride in Parkinson's disease","volume":"41","author":"Ando","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.parkreldis.2025.107872_bib202","article-title":"A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.parkreldis.2025.107872_bib203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/mds.28027","article-title":"Once-weekly subcutaneous delivery of polymer-linked rotigotine (SER-214) provides continuous plasma levels in Parkinson's disease patients","volume":"35","author":"Olanow","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2016.09.024","article-title":"In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs","volume":"513","author":"Borkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.parkreldis.2025.107872_bib205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijpharm.2016.06.010","article-title":"Apomorphine and its esters: differences in Caco-2 cell permeability and chylomicron affinity","volume":"509","author":"Borkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.parkreldis.2025.107872_bib206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/acsmedchemlett.9b00575","article-title":"Structure\u2013Functional\u2013selectivity relationship studies of novel apomorphine analogs to develop D1R\/D2R biased ligands","volume":"11","author":"Park","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.parkreldis.2025.107872_bib207","first-page":"507","article-title":"Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease","volume":"13","author":"Borkar","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib208","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2018.10.052","article-title":"New tricks for an old dog: a repurposing approach of apomorphine","volume":"843","author":"Auffret","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib209","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40263-018-0551-3","article-title":"Therapeutic management of the overlapping syndromes of atypical parkinsonism","volume":"32","author":"Giagkou","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2025.107872_bib210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11940-024-00787-6","article-title":"Management strategies for atypical parkinsonism","volume":"26","author":"Constantinides","year":"2024","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib211","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-12894-8","article-title":"Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson's disease: a systematic review and meta-analysis","volume":"272","author":"Kou","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib212","unstructured":"Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism, MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/apomorphine-as-a-diagnostic-tool-to-identify-levodopa-responsive-atypical-parkinsonism\/(accessed January 22, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib213","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2021.11.026","article-title":"Subcutaneous apomorphine in the treatment of progressive supranuclear palsy and corticobasal syndrome: a preliminary study of 7 cases","volume":"95","author":"Hubsch","year":"2022","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107872_bib214","series-title":"Value of Subcutaneous Administration of Apomorphine]","first-page":"20","article-title":"[Deglutition disorders and progressive supra nuclear paralysis","author":"Brocker","year":"1983"},{"key":"10.1016\/j.parkreldis.2025.107872_bib215","unstructured":"Atypical Response to Apomorphine in a Patient with Multiple System Atrophy, MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/atypical-response-to-apomorphine-in-a-patient-with-multiple-system-atrophy\/(accessed February 20, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib216","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mds.10113","article-title":"Paradoxical response to apomorphine in a case of atypical parkinsonism","volume":"17","author":"Cicarelli","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib217","doi-asserted-by":"crossref","first-page":"s81","DOI":"10.1007\/s100720200080","article-title":"Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders","volume":"23","author":"Lamberti","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib218","article-title":"\u201cApraxia of eyelid opening\u201d induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report","volume":"22","author":"Defazio","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib219","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.54.10.870","article-title":"The apomorphine test in parkinsonian syndromes","volume":"54","author":"D'Costa","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107872_bib220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fneur.2019.00248","article-title":"Treating disorders of consciousness with apomorphine: protocol for a double-blind randomized controlled trial using multimodal assessments","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib221","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000584","article-title":"Detecting signatures of consciousness in acute brain injury after stimulation with apomorphine and methylphenidate: protocol for a placebo-controlled, randomized, cross-over study","volume":"6","author":"Othman","year":"2024","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.parkreldis.2025.107872_bib222","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.26422","article-title":"Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease?","volume":"31","author":"Yarnall","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107872_bib223","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bmc.2018.01.028","article-title":"Mechanistic analyses of the suppression of amyloid \u03b242 aggregation by apomorphine","volume":"26","author":"Hanaki","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.parkreldis.2025.107872_bib224","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Kings Parcog groupMDS Nonmotor study group, Amyloid-\u03b2 and Parkinson's disease","volume":"266","author":"Lim","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib225","article-title":"Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107872_bib226","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s12035-023-03689-x","article-title":"Hyperphosphorylated tau inflicts intracellular stress responses that are mitigated by apomorphine","volume":"61","author":"Song","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib227","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11011-024-01372-1","article-title":"Memory enhancing and neuroprotective effects of apomorphine in a rat model of dementia","volume":"39","author":"Ikram","year":"2024","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.parkreldis.2025.107872_bib228","first-page":"829","article-title":"Attenuation of age-related cognitive decline and memory deficits through apomorphine administration","volume":"37","author":"Ikram","year":"2024","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib229","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-018-0991-2","article-title":"The effects of non-selective dopamine receptor activation by apomorphine in the mouse Hippocampus","volume":"55","author":"Arroyo-Garc\u00eda","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib230","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3233\/JAD-160344","article-title":"Apomorphine therapy for neuronal insulin resistance in a mouse model of Alzheimer's disease","volume":"58","author":"Nakamura","year":"2017","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.parkreldis.2025.107872_bib231","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/ncn3.12369","article-title":"Insulin signaling as a therapeutic target in Alzheimer's disease: efficacy of apomorphine","volume":"8","author":"Ohyagi","year":"2020","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.107872_bib232","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.22319","article-title":"Apomorphine treatment in Alzheimer mice promoting amyloid-\u03b2 degradation","volume":"69","author":"Himeno","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107872_bib233","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2174\/0929867325666180514102933","article-title":"Aporphines and Alzheimer's disease: towards a medical approach facing the future","volume":"26","author":"Nabavi","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.parkreldis.2025.107872_bib234","article-title":"Vacuum erectile devices for erectile dysfunction: recommendations from the 5th international consultation on sexual medicine, Sex. Med","author":"Wang","year":"2025","journal-title":"Rev"},{"key":"10.1016\/j.parkreldis.2025.107872_bib235","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10508-020-01817-5","article-title":"Apomorphine for the treatment of erectile dysfunction: systematic review and meta-analysis","volume":"49","author":"Guill\u00e9n","year":"2020","journal-title":"Arch. Sex. Behav."},{"key":"10.1016\/j.parkreldis.2025.107872_bib236","unstructured":"Expanding the armamentarium of clinical use of apomorphine in movement disorders., MDS Abstr. (n.d.). https:\/\/www.mdsabstracts.org\/abstract\/expanding-the-armamentarium-of-clinical-use-of-apomorphine-in-movement-disorders\/(accessed January 22, 2025)."},{"key":"10.1016\/j.parkreldis.2025.107872_bib237","doi-asserted-by":"crossref","first-page":"305","DOI":"10.14744\/cpr.2024.94596","article-title":"The effect of apomorphine therapy in the coexistence of Parkinson's disease and myasthenia gravis: a case report and review of the literature","volume":"46","author":"Demir","year":"2024","journal-title":"J. Clin. Pract. Res."},{"key":"10.1016\/j.parkreldis.2025.107872_bib238","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/REP-20-0230","article-title":"Apomorphine induces mitochondrial-dysfunction-dependent apoptosis in choriocarcinoma","volume":"160","author":"Lee","year":"2020","journal-title":"Reprod. Camb. Engl."},{"key":"10.1016\/j.parkreldis.2025.107872_bib239","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.freeradbiomed.2020.05.001","article-title":"Apomorphine facilitates loss of respiratory chain activity in human epithelial ovarian cancer and inhibits angiogenesis in vivo","volume":"154","author":"Lee","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10637-019-00784-6","article-title":"Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells, Invest","volume":"38","author":"Rodrigues-Junior","year":"2020","journal-title":"N. Drugs"},{"key":"10.1016\/j.parkreldis.2025.107872_bib241","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/antiox13070805","article-title":"Apomorphine suppresses the progression of steatohepatitis by inhibiting ferroptosis","volume":"13","author":"Maeda","year":"2024","journal-title":"Antioxid. Basel Switz."},{"key":"10.1016\/j.parkreldis.2025.107872_bib242","article-title":"Non-targeted metabolomics reveal apomorphine's therapeutic effects and lysophospholipid alterations in steatohepatitis","volume":"13","author":"Ogiso","year":"2024","journal-title":"Antioxid. Basel Switz."},{"key":"10.1016\/j.parkreldis.2025.107872_bib243","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mito.2019.07.006","article-title":"Apomorphine rescues reactive oxygen species-induced apoptosis of fibroblasts with mitochondrial disease","volume":"49","author":"Miyauchi","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.parkreldis.2025.107872_bib244","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1038\/s41598-024-55293-1","article-title":"Apomorphine is a potent inhibitor of ferroptosis independent of dopaminergic receptors","volume":"14","author":"Miyauchi","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107872_bib245","first-page":"257","article-title":"Apomorphine targets the pleiotropic bacterial regulator Hfq, antibiot","volume":"10","author":"Turbant","year":"2021","journal-title":"Basel Switz"},{"key":"10.1016\/j.parkreldis.2025.107872_bib246","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315052","article-title":"Administration of novobiocin and apomorphine mitigates cholera toxin mediated cellular toxicity: lessons from cholera toxin yeast model system","volume":"19","author":"Bhalerao","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2025.107872_bib247","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1353\/pbm.1983.0011","article-title":"A personal tribute to Dr. George C. Cotzias, clinician and scientist","volume":"27","author":"Patten","year":"1983","journal-title":"Perspect. Biol. Med."},{"key":"10.1016\/j.parkreldis.2025.107872_bib248","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.299.9.1063","article-title":"The loss of serendipity in psychopharmacology","volume":"299","author":"Klein","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2025.107872_bib249","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(24)00644-5","article-title":"In praise of serendipity","volume":"403","author":"Kneebone","year":"2024","journal-title":"Lancet"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:31:48Z","timestamp":1759624308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025006133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":247,"alternative-id":["S1353802025006133"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107872","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apomorphine: past, present and future in Parkinson's disease and beyond","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107872"}}